Clinical Trial Update: Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression [Phase 2]

View source ↗

Summary

A Phase 2 safety study evaluating VAL-083 in combination with radiotherapy for newly diagnosed glioblastoma with unmethylated MGMT expression has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma

Drugs mentioned

• VAL-083 (dianhydrogalactitol)

Snippet

Sponsor: Kintara Therapeutics, Inc. | Conditions: Glioma, Glioblastoma | Phase 2 | Status: COMPLETED